KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Equity Income (2018 - 2020)

Arbutus Biopharma (ABUS) has disclosed Equity Income for 3 consecutive years, with $2.5 million as the latest value for Q4 2020.

  • Quarterly Equity Income rose 122.68% to $2.5 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was -$45000.0 through Dec 2021, changed 0.0% year-over-year, with the annual reading at -$2.5 million for FY2020, 88.7% up from the prior year.
  • Equity Income hit $2.5 million in Q4 2020 for Arbutus Biopharma, up from -$2.5 million in the prior quarter.
  • In the past five years, Equity Income ranged from a high of $24.9 million in Q2 2018 to a low of -$11.0 million in Q4 2019.
  • Historically, Equity Income has averaged -$358777.8 across 3 years, with a median of -$2.8 million in 2018.
  • Biggest five-year swings in Equity Income: tumbled 304.74% in 2019 and later soared 122.68% in 2020.
  • Year by year, Equity Income stood at -$2.7 million in 2018, then plummeted by 304.74% to -$11.0 million in 2019, then skyrocketed by 122.68% to $2.5 million in 2020.
  • Business Quant data shows Equity Income for ABUS at $2.5 million in Q4 2020, -$2.5 million in Q3 2020, and -$11.0 million in Q4 2019.